Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Shared and unique genomic structural variants of different histological components within testicular germ cell tumours identified with mate pair sequencing.

Bryce AH, Egan JB, Smadbeck JB, Johnson SH, Murphy SJ, Harris FR, Halling GC, Terra SBSP, Cheville J, Pagliaro L, Leibovich B, Costello BA, Vasmatzis G.

Sci Rep. 2019 Mar 5;9(1):3586. doi: 10.1038/s41598-019-39956-y.

2.

HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma.

Lamberti D, Cristinziano G, Porru M, Leonetti C, Egan JB, Shi CX, Buglioni S, Amoreo CA, Castellani L, Borad MJ, Alemà S, Anastasi S, Segatto O.

Hepatology. 2019 Jan;69(1):131-142. doi: 10.1002/hep.30127. Epub 2018 Dec 14. Erratum in: Hepatology. 2019 Feb;69(2):925.

PMID:
30067876
3.

Oncolytic virotherapy in upper gastrointestinal tract cancers.

Yokoda R, Nagalo BM, Arora M, Egan JB, Bogenberger JM, DeLeon TT, Zhou Y, Ahn DH, Borad MJ.

Oncolytic Virother. 2018 Mar 23;7:13-24. doi: 10.2147/OV.S161397. eCollection 2017. Review.

4.

Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect.

Yokoda R, Nagalo BM, Vernon B, Oklu R, Albadawi H, DeLeon TT, Zhou Y, Egan JB, Duda DG, Borad MJ.

Oncolytic Virother. 2017 Nov 8;6:39-49. doi: 10.2147/OV.S145262. eCollection 2017. Review.

5.

Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.

Bryce AH, Egan JB, Borad MJ, Stewart AK, Nowakowski GS, Chanan-Khan A, Patnaik MM, Ansell SM, Banck MS, Robinson SI, Mansfield AS, Klee EW, Oliver GR, McCormick JB, Huneke NE, Tagtow CM, Jenkins RB, Rumilla KM, Kerr SE, Kocher JA, Beck SA, Fernandez-Zapico ME, Farrugia G, Lazaridis KN, McWilliams RR.

Oncotarget. 2017 Apr 18;8(16):27145-27154. doi: 10.18632/oncotarget.16057.

6.

Chemotherapy can induce weight normalization of morbidly obese mice despite undiminished ingestion of high fat diet.

Myers CE, Hoelzinger DB, Truong TN, Chew LA, Myles A, Chaudhuri L, Egan JB, Liu J, Gendler SJ, Cohen PA.

Oncotarget. 2017 Jan 17;8(3):5426-5438. doi: 10.18632/oncotarget.14576.

7.

Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib.

Bryce AH, Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, McCullough AE, Hunt KS, Ritacca NR, Barrett MT, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, Stanton ML, Cheville J, Swanson S, Schneider DE, McWilliams RR, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Von Hoff DD, Craig DW, Stewart AK, Carpten JD.

Clin Genitourin Cancer. 2017 Aug;15(4):e727-e734. doi: 10.1016/j.clgc.2016.11.001. Epub 2016 Dec 1. No abstract available.

8.

Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma.

Egan JB, Marks DL, Hogenson TL, Vrabel AM, Sigafoos AN, Tolosa EJ, Carr RM, Safgren SL, Hesles EE, Almada LL, Romecin-Duran PA, Iguchi E, Ala'Aldeen A, Kocher JA, Oliver GR, Prodduturi N, Mead DW, Hossain A, Huneke NE, Tagtow CM, Ailawadhi S, Ansell SM, Banck MS, Bryce AH, Carballido EM, Chanan-Khan AA, Curtis KK, Resnik E, Gawryletz CD, Go RS, Halfdanarson TR, Ho TH, Joseph RW, Kapoor P, Mansfield AS, Meurice N, Nageswara Rao AA, Nowakowski GS, Pardanani A, Parikh SA, Cheville JC, Feldman AL, Ramanathan RK, Robinson SI, Tibes R, Finnes HD, McCormick JB, McWilliams RR, Jatoi A, Patnaik MM, Silva AC, Wieben ED, McAllister TM, Rumilla KM, Kerr SE, Lazaridis KN, Farrugia G, Stewart AK, Clark KJ, Kennedy EJ, Klee EW, Borad MJ, Fernandez-Zapico ME.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00018. Epub 2017 Aug 1.

9.

Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers.

Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, Ritacca NR, McCullough AE, Barrett MT, Hunt KS, Champion MD, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, McWilliams RR, Lazaridis KN, Ramanathan RK, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Valdez R, Jaroszewski DE, Von Hoff DD, Craig DW, Stewart AK, Carpten JD, Bryce AH.

Sci Rep. 2016 Dec 23;6(1):25. doi: 10.1038/s41598-016-0021-4.

10.

PANDA: pathway and annotation explorer for visualizing and interpreting gene-centric data.

Hart SN, Moore RM, Zimmermann MT, Oliver GR, Egan JB, Bryce AH, Kocher JA.

PeerJ. 2015 May 19;3:e970. doi: 10.7717/peerj.970. eCollection 2015.

11.

Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).

Kortüm KM, Langer C, Monge J, Bruins L, Zhu YX, Shi CX, Jedlowski P, Egan JB, Ojha J, Bullinger L, Kull M, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E.

Ann Hematol. 2015 Jul;94(7):1205-11. doi: 10.1007/s00277-015-2344-9. Epub 2015 Mar 7.

12.

Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.

Kortüm KM, Langer C, Monge J, Bruins L, Egan JB, Zhu YX, Shi CX, Jedlowski P, Schmidt J, Ojha J, Bullinger L, Liebisch P, Kull M, Champion MD, Van Wier S, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E.

Br J Haematol. 2015 Feb;168(4):507-10. doi: 10.1111/bjh.13171. Epub 2014 Oct 10.

13.

Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.

Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, McCullough AE, Barrett MT, Hunt K, Patel MD, Young SW, Collins JM, Silva AC, Condjella RM, Block M, McWilliams RR, Lazaridis KN, Klee EW, Bible KC, Harris P, Oliver GR, Bhavsar JD, Nair AA, Middha S, Asmann Y, Kocher JP, Schahl K, Kipp BR, Barr Fritcher EG, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Phillips L, McDonald J, Adkins J, Mastrian SD, Placek P, Watanabe AT, Lobello J, Han H, Von Hoff D, Craig DW, Stewart AK, Carpten JD.

PLoS Genet. 2014 Feb 13;10(2):e1004135. doi: 10.1371/journal.pgen.1004135. eCollection 2014 Feb.

14.

Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements.

Egan JB, Barrett MT, Champion MD, Middha S, Lenkiewicz E, Evers L, Francis P, Schmidt J, Shi CX, Van Wier S, Badar S, Ahmann G, Kortuem KM, Boczek NJ, Fonseca R, Craig DW, Carpten JD, Borad MJ, Stewart AK.

PLoS One. 2014 Feb 5;9(2):e87113. doi: 10.1371/journal.pone.0087113. eCollection 2014.

15.

Simultaneous characterization of somatic events and HPV-18 integration in a metastatic cervical carcinoma patient using DNA and RNA sequencing.

Liang WS, Aldrich J, Nasser S, Kurdoglu A, Phillips L, Reiman R, McDonald J, Izatt T, Christoforides A, Baker A, Craig C, Egan JB, Chase DM, Farley JH, Bryce AH, Stewart AK, Borad MJ, Carpten JD, Craig DW, Monk BJ.

Int J Gynecol Cancer. 2014 Feb;24(2):329-38. doi: 10.1097/IGC.0000000000000049.

16.

Lessons from next-generation sequencing analysis in hematological malignancies.

Braggio E, Egan JB, Fonseca R, Stewart AK.

Blood Cancer J. 2013 Jul 19;3:e127. doi: 10.1038/bcj.2013.26.

17.

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.

Schmidt J, Braggio E, Kortuem KM, Egan JB, Zhu YX, Xin CS, Tiedemann RE, Palmer SE, Garbitt VM, McCauley D, Kauffman M, Shacham S, Chesi M, Bergsagel PL, Stewart AK.

Leukemia. 2013 Dec;27(12):2357-65. doi: 10.1038/leu.2013.172. Epub 2013 Jun 11.

18.

Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease.

Egan JB, Kortuem KM, Kurdoglu A, Izatt T, Aldrich J, Reiman R, Phillips L, Baker A, Shi CX, Schmidt J, Liang WS, Craig DW, Carpten JD, Stewart AK.

Br J Haematol. 2013 Jun;161(5):748-51. doi: 10.1111/bjh.12291. Epub 2013 Mar 11. No abstract available.

19.

Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing.

Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer JA, Legendre C, Posner R, Hostetter GH, Baker A, Egan JB, Han H, Lake D, Stites EC, Ramanathan RK, Fonseca R, Stewart AK, Von Hoff D.

PLoS One. 2012;7(10):e43192. doi: 10.1371/journal.pone.0043192. Epub 2012 Oct 10.

20.

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.

Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, Middha S, Asmann Y, Schmidt J, Braggio E, Keats JJ, Fonseca R, Bergsagel PL, Craig DW, Carpten JD, Stewart AK.

Blood. 2012 Aug 2;120(5):1060-6. doi: 10.1182/blood-2012-01-405977. Epub 2012 Apr 23.

21.

Clonal competition with alternating dominance in multiple myeloma.

Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL.

Blood. 2012 Aug 2;120(5):1067-76. doi: 10.1182/blood-2012-01-405985. Epub 2012 Apr 12.

22.

Transcriptional interference by RNA polymerase pausing and dislodgement of transcription factors.

Palmer AC, Egan JB, Shearwin KE.

Transcription. 2011 Jan-Feb;2(1):9-14. doi: 10.4161/trns.2.1.13511.

23.

Association between polymorphic variation in VDR and RXRA and circulating levels of vitamin D metabolites.

Hibler EA, Jurutka PW, Egan JB, Hu C, LeRoy EC, Martinez ME, Thompson PA, Jacobs ET.

J Steroid Biochem Mol Biol. 2010 Jul;121(1-2):438-41. doi: 10.1016/j.jsbmb.2010.03.052. Epub 2010 Mar 20.

24.

The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the "Fountain of Youth" to mediate healthful aging.

Haussler MR, Haussler CA, Whitfield GK, Hsieh JC, Thompson PD, Barthel TK, Bartik L, Egan JB, Wu Y, Kubicek JL, Lowmiller CL, Moffet EW, Forster RE, Jurutka PW.

J Steroid Biochem Mol Biol. 2010 Jul;121(1-2):88-97. doi: 10.1016/j.jsbmb.2010.03.019. Epub 2010 Mar 20.

25.

Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence.

Egan JB, Thompson PA, Ashbeck EL, Conti DV, Duggan D, Hibler E, Jurutka PW, Leroy EC, Martínez ME, Mount D, Jacobs ET.

Cancer Res. 2010 Feb 15;70(4):1496-504. doi: 10.1158/0008-5472.CAN-09-3264. Epub 2010 Feb 9.

26.

Vitamin D receptor ligands, adenomatous polyposis coli, and the vitamin D receptor FokI polymorphism collectively modulate beta-catenin activity in colon cancer cells.

Egan JB, Thompson PA, Vitanov MV, Bartik L, Jacobs ET, Haussler MR, Gerner EW, Jurutka PW.

Mol Carcinog. 2010 Apr;49(4):337-52. doi: 10.1002/mc.20603.

27.

Potent transcriptional interference by pausing of RNA polymerases over a downstream promoter.

Palmer AC, Ahlgren-Berg A, Egan JB, Dodd IB, Shearwin KE.

Mol Cell. 2009 Jun 12;34(5):545-55. doi: 10.1016/j.molcel.2009.04.018.

28.

Presence of a TA haplotype in the APC gene containing the common 1822 polymorphism and colorectal adenoma.

Egan JB, Jacobs ET, Martínez ME, Gerner EW, Jurutka PW, Thompson PA.

Cancer Res. 2008 Jul 15;68(14):6006-13. doi: 10.1158/0008-5472.CAN-08-1084.

29.
30.

The structural basis of cooperative regulation at an alternate genetic switch.

Pinkett HW, Shearwin KE, Stayrook S, Dodd IB, Burr T, Hochschild A, Egan JB, Lewis M.

Mol Cell. 2006 Mar 3;21(5):605-15.

31.

Functional alignment of regulatory networks: a study of temperate phages.

Trusina A, Sneppen K, Dodd IB, Shearwin KE, Egan JB.

PLoS Comput Biol. 2005 Dec;1(7):e74. Epub 2005 Dec 23.

32.

Transcriptional interference--a crash course.

Shearwin KE, Callen BP, Egan JB.

Trends Genet. 2005 Jun;21(6):339-45. Review.

33.

Revisited gene regulation in bacteriophage lambda.

Dodd IB, Shearwin KE, Egan JB.

Curr Opin Genet Dev. 2005 Apr;15(2):145-52. Review.

PMID:
15797197
34.

A mathematical model for transcriptional interference by RNA polymerase traffic in Escherichia coli.

Sneppen K, Dodd IB, Shearwin KE, Palmer AC, Schubert RA, Callen BP, Egan JB.

J Mol Biol. 2005 Feb 18;346(2):399-409. Epub 2004 Dec 23.

PMID:
15670592
35.
36.

Cooperativity in long-range gene regulation by the lambda CI repressor.

Dodd IB, Shearwin KE, Perkins AJ, Burr T, Hochschild A, Egan JB.

Genes Dev. 2004 Feb 1;18(3):344-54.

37.
38.
39.

The helix-turn-helix motif of the coliphage 186 immunity repressor binds to two distinct recognition sequences.

Shearwin KE, Dodd IB, Egan JB.

J Biol Chem. 2002 Feb 1;277(5):3186-94. Epub 2001 Nov 7.

40.

Establishing lysogenic transcription in the temperate coliphage 186.

Neufing PJ, Shearwin KE, Egan JB.

J Bacteriol. 2001 Apr;183(7):2376-9.

41.
42.
43.

The late-expressed region of the temperate coliphage 186 genome.

Portelli R, Dodd IB, Xue Q, Egan JB.

Virology. 1998 Aug 15;248(1):117-30.

44.

The Tum protein of coliphage 186 is an antirepressor.

Shearwin KE, Brumby AM, Egan JB.

J Biol Chem. 1998 Mar 6;273(10):5708-15.

46.

The dual role of Apl in prophage induction of coliphage 186.

Reed MR, Shearwin KE, Pell LM, Egan JB.

Mol Microbiol. 1997 Feb;23(4):669-81.

47.

The CII protein of bacteriophage 186 establishes lysogeny by activating a promoter upstream of the lysogenic promoter.

Neufing PJ, Shearwin KE, Camerotto J, Egan JB.

Mol Microbiol. 1996 Aug;21(4):751-61.

PMID:
8878038
48.

DNA binding by the coliphage 186 repressor protein CI.

Dodd IB, Egan JB.

J Biol Chem. 1996 May 10;271(19):11532-40.

49.

Supplemental Content

Support Center